ALSO NOTED: Wyeth plant sold to Akrimax; Schering suit settled in lawyers' favor;

> Wyeth Pharmaceutical sold its Rouses Point, NY, plant to Akrimax Pharmaceutical, which intends to continue operating the facility and retain most of its 900 employees. Report

> Shareholders sued Schering-Plough, but only their lawyers got paid. The drug makers have to hand over $9.5 million to plaintiffs counsel and pledge to reform its governance. Report

> Stryker, which makes artificial knees and hips, got an FDA warning letter stemming from quality problems at its Mahwah, N.J., plant. Report

> India's Natco Pharma has applied for a compulsory license on Roche's lung cancer med Tarceva, which it intends to copy and export to Nepal. Report

> Shire announced its intent to expand in Latin America; the company recently added Mexico City operations to its portfolio in South America. Release

> OncoMed's $1.4 billion antibody development pact with GlaxoSmithKline has put a premium on preclinical programs. Report

> A number of top European pharmaceutical companies and CRS are bringing a close to an 80-year era of animal tests for acute toxicity. Report

> Don't look to Europe for many new chemical entity approvals in '08, analysts say. Report 

And Finally... Could asthma and allergy prevention start in the womb, rather than with once-a-day meds? Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.